FierceBiotechOriginal article
{"a":[{"_":"‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discovery ","$":{"href":"/biotech/were-not-afraid-competition-biocryst-ceo-sets-out-strategy-after-scrapping-internal","hreflang":"en"}}]}
Neutral
AI Analysis
Summary
BioCryst CEO Charlie Gayer announced the company is shutting down its internal discovery efforts but stated the company remains committed to science and R&D, signaling a strategic pivot rather than a complete exit from research.
Importance:3/10
Sentiment:
0.00
strategyinternal discoveryR&Dbusiness restructuring
Related Companies
Read the original article
Published by FierceBiotech on August 14, 2026 10:20 AM
